Cambridge Equities, LP - 10 Nov 2025 SCHEDULE 13D/A Report for ImmunityBio, Inc. Common Stock, par value $0.0001 per share (IBRX)

Filing Manager
Cambridge Equities, LP
Reporting Manager
Patrick Soon-Shiong
Security
ImmunityBio, Inc. Common Stock, par value $0.0001 per share
Symbol
IBRX
Shares outstanding
1,079,784,035 shares
Disclosed Ownership
743,971,200 shares
Ownership
69%
Form type
SCHEDULE 13D/A
Filing time
10 Nov 2025, 19:43:30 UTC
Date of event
10 Nov 2025
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Managers (7)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Cambridge Equities, LP 27% 261,705,814 0 261,705,814 /s/ Charles Kenworthy Charles Kenworthy, Manager of MP 13 Ventures, LLC, the General Partner of Cambridge Equities, LP 0001629222
MP 13 Ventures, LLC 27% 261,705,814 0 261,705,814 /s/ Charles Kenworthy Charles Kenworthy, Manager 0001629186
NantWorks, LLC 10% 98,535,253 0 98,535,253 /s/ Robert Morse Robert Morse, CFO of NantWorks, LLC 0001675760
NantMobile, LLC 4.8% 47,557,934 0 47,557,934 /s/ Robert Morse Robert Morse, CFO of NantMobile, LLC 0001567221
Nant Capital, LLC 32% 339,464,529 0 339,465,529 /s/ Charles Kenworthy Charles Kenworthy, Manager of Nant Capital, LLC 0001675758
California Capital Equity, LLC 11% 106,511,412 0 106,511,412 /s/ Charles Kenworthy Charles Kenworthy, Manager of California Capital Equity, LLC 0001517764
Patrick Soon-Shiong 69% 743,971,200 30,670,119 713,301,081 /s/ Patrick Soon-Shiong Patrick Soon-Shiong 0001189020